AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/coms2/summary_0286-26208066_ITM" title="Facts and information about Press Release: Cephalon reacquires rights to ACTIQ in key European markets; deal further strengthens international marketing presence.">Press Release: Cephalon reacquires rights to ACTIQ in key European markets; deal further strengthens international marketing presence.</a>
Close
Set up an RSS feed that alerts you when new articles from Asia Africa Intelligence Wire are available.
Frequently asked questions about RSS feeds
Press Release: Cephalon reacquires rights to ACTIQ in key European markets; deal further strengthens international marketing presence.
(From Chemical Business NewsBase: Press Release)
Cephalon Inc has reacquired all rights to its cancer pain product ACTIQ (oral transmucosal fentanyl citrate) [C-II] in 12 countries, principally in Europe, from Elan Pharma International Ltd, a subsidiary of Elan Corp plc. Under the agreement, Cephalon reacquired rights to ACTIQ in Austria, Belgium, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Switzerland, UK, Philippines, and Taiwan and paid Elan $50 M in cash. Cephalon already markets ACTIQ in the US and will market the drug directly in the UK, Germany, and France. ACTIQ was granted marketing ...
Related articles from newspapers, magazines, journals, and more
For more facts and information, see all results
- PRESS RELEASE: Actiq receives marketing authorization in 16 European countries.
- News wire article from: Chemical Business Newsbase July 9, 2001 700+ words
Cephalon Inc announced Actiq (oral transmucosal fentanyl citrate...follows initial approval on 9 Oct 2000 of Actiq for marketing and sale in the UK. Cephalon...marketing and distribution partnerships for Actiq with the following companies: Elan Pharmaceuticals...
- PRESS RELEASE: Cephalon announces marketing and distribution agreement for...
- News wire article from: Chemical Business Newsbase June 18, 2001 700+ words
...rights to market, sell and distribute Actiq (oral transmucosal fentanyl citrate...Australia for Australia and New Zealand. Actiq is marketed in the US by Cephalon and in the UK through Elan Pharma Ltd. Actiq, available via Cephalon's patented...
- Cephalon Files Supplemental New Drug Application for Sugar-Free Formulation of...
- Press release article from: PR Newswire December 1, 2004 700+ words
...5855) or at http://www.actiq.com/. Cephalon, Inc...tiagabine hydrochloride) and ACTIQ(R) and more than 20 products...of current condition, this press release may contain forward-looking...approval, including for the ACTIQ sNDA, manufacturing development...
- ANESTA RECEIVES ACTIQ APPROVAL IN THE UK.
- Press release article from: PR Newswire October 10, 2000 700+ words
...London, October, 10. This press release is transmitted on behalf...marketing authorisation for Actiq(R) (oral transmucosal fentanyl citrate). Actiq is the first product approved...NYSE: ELN) will market Actiq in the UK and market launch...
- Cephalon Transfers Manufacture of ACTIQ(R) to its Salt Lake City Facility;...
- Press release article from: PR Newswire April 2, 2003 700+ words
...greatest risk from improper use of ACTIQ, as with all opioid-based...tiagabine hydrochloride) and ACTIQ(R) (oral transmucosal fentanyl...of current condition, this press release contains forward-looking...ability to satisfy demand for ACTIQ and the impact of recent changes...
- Cephalon Announces Marketing and Distribution Agreement For ACTIQ(R) in...
- Press release article from: PR Newswire June 12, 2001 700+ words
...partnerships dedicated to the launch of ACTIQ." "ACTIQ is an important drug for Australia...activities to successfully launch ACTIQ in this territory." Orphan Australia...statements of current condition, this press release may contain forward-looking...
- ACTIQ RECEIVES MARKETING AUTHORISATION IN 16 EUROPEAN COUNTRIES.
- Press release article from: PR Newswire June 28, 2001 700+ words
...London, June 28. This press release is transmitted on behalf...announced today that ACTIQ(R) (oral transmucosal...potent opioid analgesic. ACTIQ utilises a patented...observed by patients using ACTIQ are somnolence, nausea...current condition, this press release may contain ...
- Study finds 90% of Actiq lollipop prescriptions are off-label.
- News wire article from: Chemical Business Newsbase January 16, 2007 700+ words
...Chemical Business NewsBase - Press Release) A recent Prime Therapeutics...off-label prescribing for Actiq among patients taking the powerful...painkilling lollipop. Prescribing Actiq according to FDA guidelines...programmes that manage the use of Actiq and other dangerous drugs in...
- Cephalon Receives Approvable Letter to Market Sugar-Free Formulation of...
- Press release article from: PR Newswire March 25, 2005 700+ words
...intensity with continued use of ACTIQ, as the patient is titrated...hydrochloride) Tablets and ACTIQ(R) and more than 20 products...of current condition, this press release may contain forward-looking...sugar-free formulation of ACTIQ, interpretation of clinical...
- Cephalon Receives FDA Approval to Market Sugar-Free Formulation of ACTIQ(R).
- Press release article from: PR Newswire September 12, 2005 700+ words
...intensity with continued use of ACTIQ, as the patient is titrated...tiagabine hydrochloride), ACTIQ, and TRISENOX(R) (arsenic...of current condition, this press release may contain forward-looking...sugar-free formulation of ACTIQ. You may identify some of...